Beatrice Li
Team Lead of Protein Science & Structural Biology Confo Therapeutics
Dr. Beatrice Li is the Team Lead and Principal Scientist of Protein Science & Structural Biology at Confo Therapeutics. With over a decade of experience across academia and industry, Dr. Li has significantly advanced early-stage drug discovery by integrating structural biology, biophysics, and molecular biology. She previously held senior roles at Exscientia and Evotec, leading multi-disciplinary teams, and also contributes as an editor at Bio-protocol, promoting transparency in scientific methods.
Seminars
Wednesday 13th January 2027
Chair’s Opening Remarks
8:50 am
Wednesday 13th January 2027
Panel Discussion: Building Trust in AI Predictions by Validation & Benchmarking
4:00 pm
- Establish rigorous validation frameworks that identify the 50% of AI outputs that are hallucinations, ensuring your teams trust and adopt computational tools rather than dismissing them due to poor early experiences
- Learn how to benchmark AI predictions against experimental data, understanding which use cases deliver value and which remain aspirational
- Discover strategies to educate scientific teams on AI capabilities and limitations, setting realistic expectations and driving productive adoption while avoiding the “magic bullet” trap
Wednesday 13th January 2027
Chairs Closing Remarks
5:00 pm
Thursday 14th January 2027
Chair’s Opening Remarks
8:50 am
Thursday 14th January 2027
Advancing Biophysical Characterisation Technologies to Decode Challenging Membrane Targets & Increase Confidence in Drug Discovery
1:30 pm
- Master emerging techniques for detecting small molecule binding to GPCRs and membrane proteins, overcoming the characterisation challenges that plague these high-value targets representing 30% of marketed drugs
- Learn how nanodisc technologies preserve native protein conformations and enable structural studies, improving the physiological relevance of your biophysical data and reducing false positives
- Discover strategies to stabilise dynamic GPCR conformations using conformer technology and nanobodies, enabling structure determination of specific functional states for agonist versus antagonist design
Thursday 14th January 2027
Chairs’ Closing Remarks
3:00 pm
